Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.

Jeong Mi Kim Sang Soo KimJong Ho KimMi Kyung KimTae Nyun KimSoon Hee LeeChang Won LeeJa Young ParkEun Sook KimKwang Jae LeeYoung Sik ChoiDuk Kyu KimIn-Joo Kim

Published in: Diabetes & metabolism journal (2019)

Among patients with T2DM inadequately controlled using metformin plus alogliptin, the addition of pioglitazone provided comparable glycemic control and various benefits (improvements in lipid profiles, insulin resistance, and hypoglycemia risk) relative to the addition of glimepiride.

Keyphrases

glycemic control
combination therapy
insulin resistance
type diabetes
open label
blood glucose
adipose tissue
weight loss
metabolic syndrome
clinical trial
high fat diet
polycystic ovary syndrome
skeletal muscle
phase ii study
cross sectional
phase ii
high fat diet induced
double blind
squamous cell carcinoma